EPS for Nektar Therapeutics (NKTR) Expected At $-0.58

October 13, 2018 - By Hazel Jackson

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.13 in 2018 Q2. Its down 0.30, from 1.43 in 2018Q1. It dived, as 54 investors sold Nektar Therapeutics shares while 100 reduced holdings. 82 funds opened positions while 92 raised stakes. 157.21 million shares or 2.48% more from 153.40 million shares in 2018Q1 were reported.
Moreover, California State Teachers Retirement Systems has 0.03% invested in Nektar Therapeutics (NASDAQ:NKTR) for 249,715 shares. Tudor Inv Et Al accumulated 0.19% or 109,071 shares. Bridger Mgmt Ltd Llc invested 3% in Nektar Therapeutics (NASDAQ:NKTR). Hanseatic Mgmt Svcs, New Mexico-based fund reported 3,191 shares. South Dakota Inv Council holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 5,100 shares. Teachers Retirement System Of The State Of Kentucky holds 0.02% in Nektar Therapeutics (NASDAQ:NKTR) or 30,500 shares. British Columbia Invest Mgmt Corp holds 0.02% or 48,383 shares in its portfolio. Utah Retirement Systems owns 28,900 shares. Great West Life Assurance Can has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Louisiana State Employees Retirement Sys has 0.02% invested in Nektar Therapeutics (NASDAQ:NKTR) for 9,500 shares. Rampart Inv Management Comm Ltd holds 0.05% in Nektar Therapeutics (NASDAQ:NKTR) or 10,999 shares. Andra Ap has 15,800 shares for 0.02% of their portfolio. 32,965 are held by Qs Investors Lc. Dupont has 1,717 shares for 0% of their portfolio. Perceptive Advsr Lc reported 6,057 shares.

Since April 16, 2018, it had 1 buy, and 24 insider sales for $39.19 million activity. 10,000 shares were sold by GREER R SCOTT, worth $673,900 on Tuesday, September 4. Hora Maninder sold $338,563 worth of stock. On Thursday, September 20 Lingnau Lutz sold $512,820 worth of Nektar Therapeutics (NASDAQ:NKTR) or 9,000 shares. 12,791 shares were sold by ROBIN HOWARD W, worth $1.07 million. Another trade for 4,917 shares valued at $410,029 was made by Nicholson John on Wednesday, May 16. On Thursday, May 3 CHESS ROBERT sold $2.07 million worth of Nektar Therapeutics (NASDAQ:NKTR) or 25,000 shares.

Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report $-0.58 EPS on November, 6.They anticipate $0.95 EPS change or 256.76 % from last quarter’s $0.37 EPS. After having $5.33 EPS previously, Nektar Therapeutics’s analysts see -110.88 % EPS growth. The stock increased 2.11% or $1.01 during the last trading session, reaching $48.91. About 1.85M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 187.03% since October 14, 2017 and is uptrending. It has outperformed by 171.41% the S&P500.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 6 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Nektar Therapeutics had 7 analyst reports since April 20, 2018 according to SRatingsIntel. As per Tuesday, June 5, the company rating was maintained by Canaccord Genuity. As per Monday, June 4, the company rating was maintained by Cowen & Co. The rating was maintained by JP Morgan with “Overweight” on Monday, June 4. Canaccord Genuity maintained Nektar Therapeutics (NASDAQ:NKTR) rating on Friday, May 11. Canaccord Genuity has “Buy” rating and $9400 target. The company was downgraded on Monday, June 11 by H.C. Wainwright.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $8.44 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It has a 9.1 P/E ratio. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

More recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Nasdaq.com which released: “Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?” on October 02, 2018. Also Seekingalpha.com published the news titled: “Refuting Nektar’s Apparent Response To Our Initial Report” on October 04, 2018. Seekingalpha.com‘s news article titled: “Pegging The Value Of NKTR-214 At Zero” with publication date: October 02, 2018 was also an interesting one.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News